What SEC filings does Cytokinetics, Incorporated submit to the SEC?

Cytokinetics, Incorporated (CYTK) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about CYTK?

A Form 4 for CYTK discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Cytokinetics, Incorporated?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for CYTK?

The 10-K is Cytokinetics, Incorporated's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all CYTK SEC filings directly on EDGAR?

You can view all historical Cytokinetics, Incorporated filings on the SEC EDGAR company page for CYTK. Each filing card on this page links directly to the original SEC document.

How often does Cytokinetics, Incorporated file with the SEC?

Cytokinetics, Incorporated files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling CYTK shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

CYTK SEC Filing News — Cytokinetics, Incorporated

Latest SEC filings for Cytokinetics, Incorporated (CYTK) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-13.

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a pot…

Sector: Healthcare Industry: Biotechnology Market Cap: $8.7B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for CYTK currently lean bearish. Of the 20 filing records displayed, 14 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

CYTK Filing Activity Snapshot 2026-08-06 — 2026-10-13

Insider Transactions (Form 4)

0 buys vs 13 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$7.34M

Blum Robert I (Director, President & CEO) · 2026-09-15

105,426 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for Cytokinetics, Incorporated.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 13 open-market sale. 13 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×13: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-10-13

CYTK insider Blum Robert I (Director, President & CEO) sold 7,500 shares (~$471.6K)

Blum Robert I, listed as Director, President & CEO at CYTOKINETICS INC, reported an open-market sale of 7,500 CYTK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	7,500	$10.60	$79.5K
`S`	Open-market sale	7,500	$62.88	$471.6K
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	7,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Blum Robert I (Director, President & CEO) Shares: 7,500 Est. Value: $471.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-06

CYTK insider Malik Fady Ibraham (EVP Research & Development) sold 3,500 shares (~$214.8K)

Malik Fady Ibraham, listed as EVP Research & Development at CYTOKINETICS INC, reported an open-market sale of 3,500 CYTK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	3,500	$7.80	$27.3K
`S`	Open-market sale	3,500	$61.38	$214.8K
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	3,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Malik Fady Ibraham (EVP Research & Development) Shares: 3,500 Est. Value: $214.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-28

CYTK insider Blum Robert I (Director, President & CEO) sold 7,500 shares (~$490.9K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	7,500	$10.60	$79.5K
`S`	Open-market sale	7,500	$65.46	$490.9K
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	7,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Blum Robert I (Director, President & CEO) Shares: 7,500 Est. Value: $490.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-22

CYTK insider Malik Fady Ibraham (EVP Research & Development) sold 3,500 shares (~$239.0K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	3,500	$7.80	$27.3K
`S`	Open-market sale	3,500	$68.29	$239.0K
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	3,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Malik Fady Ibraham (EVP Research & Development) Shares: 3,500 Est. Value: $239.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-15

CYTK insider Landry Robert E (Director) sold 1,000 shares (~$72.1K)

Landry Robert E, listed as Director at CYTOKINETICS INC, reported an open-market sale of 1,000 CYTK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,000	$72.13	$72.1K

Filing: Form 4 (Insider Transaction) Insider: Landry Robert E (Director) Shares: 1,000 Est. Value: $72.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-15

CYTK insider Blum Robert I (Director, President & CEO) sold 105,426 shares (~$7.34M)

Blum Robert I, listed as Director, President & CEO at CYTOKINETICS INC, reported an open-market sale of 105,426 CYTK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	7,500	$10.60	$79.5K
`S`	Open-market sale	7,500	$73.44	$550.8K
`G`	Gift	1,350	—	—
`G`	Gift	97,926	—	—
`G`	Gift	97,926	—	—
`S`	Open-market sale	97,926	$69.33	$6.79M
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	7,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Blum Robert I (Director, President & CEO) Shares: 105,426 Est. Value: $7.34M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-11

CYTK insider Landry Robert E (Director) sold 1,000 shares (~$74.7K)

Landry Robert E, listed as Director at CYTOKINETICS INC, reported an open-market sale of 1,000 CYTK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,000	$74.66	$74.7K

Filing: Form 4 (Insider Transaction) Insider: Landry Robert E (Director) Shares: 1,000 Est. Value: $74.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-08

CYTK insider Malik Fady Ibraham (EVP Research & Development) sold 3,500 shares (~$264.1K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	3,500	$7.80	$27.3K
`S`	Open-market sale	3,500	$75.46	$264.1K
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	3,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Malik Fady Ibraham (EVP Research & Development) Shares: 3,500 Est. Value: $264.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-01

CYTK insider PARSHALL B LYNNE (Director) sold 5,000 shares (~$357.4K)

PARSHALL B LYNNE, listed as Director at CYTOKINETICS INC, reported an open-market sale of 5,000 CYTK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	5,000	$71.48	$357.4K

Filing: Form 4 (Insider Transaction) Insider: PARSHALL B LYNNE (Director) Shares: 5,000 Est. Value: $357.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-31

CYTK insider Callos Andrew (EVP, Chief Commercial Officer) sold 10,000 shares (~$702.4K)

Callos Andrew, listed as EVP, Chief Commercial Officer at CYTOKINETICS INC, reported an open-market sale of 10,000 CYTK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	10,000	$23.26	$232.6K
`S`	Open-market sale	10,000	$70.24	$702.4K
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	10,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Callos Andrew (EVP, Chief Commercial Officer) Shares: 10,000 Est. Value: $702.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-31

CYTK insider Blum Robert I (Director, President & CEO) sold 7,500 shares (~$526.8K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	7,500	$10.60	$79.5K
`S`	Open-market sale	7,500	$70.24	$526.8K
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	7,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Blum Robert I (Director, President & CEO) Shares: 7,500 Est. Value: $526.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-18

CYTK insider Malik Fady Ibraham (EVP Research & Development) sold 3,500 shares (~$265.4K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	3,500	$7.80	$27.3K
`S`	Open-market sale	3,500	$75.82	$265.4K
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	3,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Malik Fady Ibraham (EVP Research & Development) Shares: 3,500 Est. Value: $265.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-10

CYTK insider Blum Robert I (Director, President & CEO) sold 7,500 shares (~$575.7K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	7,500	$10.60	$79.5K
`S`	Open-market sale	7,500	$76.76	$575.7K
`M`	Option exercise derivative · Non-Qualified Stock Option (Right to Buy)	7,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Blum Robert I (Director, President & CEO) Shares: 7,500 Est. Value: $575.7K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 4 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Cytokinetics, Incorporated has 4 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-13

CYTK Form 144 filed for proposed insider sale by ROBERT BLUM (22,500 shares) ~$1.42M

ROBERT BLUM filed a Form 144 with the SEC indicating intent to sell CYTK (CYTOKINETICS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ROBERT BLUM Shares: 22,500 Est. Value: $1.42M

View on SEC EDGAR → Open Filing Document →

Form 144 Large Proposed Insider Sale 2026-09-15

CYTK Form 144 filed for proposed insider sale by Robert I. Blum (97,926 shares) ~$7.09M

Robert I. Blum filed a Form 144 with the SEC indicating intent to sell CYTK (CYTOKINETICS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Robert I. Blum Shares: 97,926 Est. Value: $7.09M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-11

CYTK Form 144 filed for proposed insider sale by ROBERT LANDRY (2,000 shares) ~$147.2K

ROBERT LANDRY filed a Form 144 with the SEC indicating intent to sell CYTK (CYTOKINETICS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ROBERT LANDRY Shares: 2,000 Est. Value: $147.2K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-01

CYTK Form 144 filed for proposed insider sale by B LYNNE PARSHALL (5,000 shares) ~$354.6K

B LYNNE PARSHALL filed a Form 144 with the SEC indicating intent to sell CYTK (CYTOKINETICS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: B LYNNE PARSHALL Shares: 5,000 Est. Value: $354.6K

View on SEC EDGAR → Open Filing Document →

Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Cytokinetics, Incorporated. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-28

CYTK filed 8-K — material company event

CYTOKINETICS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-13

CYTK filed 8-K — material company event

CYTOKINETICS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Cytokinetics, Incorporated.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

CYTK filed Quarterly Report (10-Q)

CYTOKINETICS INC filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Cytokinetics, Incorporated's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on CYTK. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — CYTK SEC Filings

More Tools for CYTK

CYTK Full Stock Analysis CYTK Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper CYTK analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the CYTK stock analysis page.

CYTK Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer